Beacon Pharmaceuticals of Bangladesh has announced plans to establish a second manufacturing unit to increase its capacity for cancer drug production. The company intends to invest 250 crore taka in this expansion project. This investment signifies a commitment to bolstering the availability of critical cancer medications within Bangladesh. The new unit will contribute to meeting the growing demand for these life-saving drugs domestically. Beacon Pharma aims to reduce reliance on imports and strengthen the country’s pharmaceutical sector. This expansion is expected to create new employment opportunities and stimulate economic growth in Bangladesh. The company's initiative represents a significant step towards improving cancer care accessibility for patients across the nation.